Mumbai: Marksans Pharma Limited has announced that its … mg Film-coated Tablets). Marksans Pharma Limited, headquartered at Mumbai, India … , manufacturing & marketing of generic pharmaceutical formulation in the global markets …

In this briefing: IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update 1. IZOZF: Initiating Coverage: Breakthrough Technology for Breast Cancer Screening Izotropic is a medical device company that has developed an innovative machine that will allow for women to have more accurate and comfortable screenings for breast cancer. For years, women with dense breasts have had cancers missed or have had to undergo additional, expensive tests. With the Izotropic machine, costs for insurance companies will go down, accuracy will be greatly increased, and comfort will improve. 2. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm.

In this briefing: Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential GENOVA (9341 JP): 1H FY03/26 flash update Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs 1. Fortis Healthcare Ltd - Strong Quarter with Margin Expansion Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm. Stable ARPOB and Occupancy: ARPOB stood at Rs 68,800, marking a 5.9% YoY increase, while occupancy rose to 71% (up 100 bps QoQ), supported by a 13% YoY growth in occupied bed days. EBITDA margin expanded to 23.9%, up 200 bps YoY and 120 bps QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: RITES Ltd - Strong Orderbook to Drive Growth Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth Telecom Industry Snapshot- September 2025: Jio and Airtel Drive Data-Led Growth UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. RITES Ltd - Strong Orderbook to Drive Growth Strong Order Book: In Q2FY26, the company secured over 150 new orders worth Rs 851 Cr, taking the total order book to Rs 9,090 Cr and ensuring strong revenue visibility for the next 2–2.5 years. Notably, 34% of the order book comprises the high-margin consultancy segment, underscoring its profitability profile. Backed by a robust pipeline and increasing opportunities across the infrastructure space, the company remains well-positioned to deliver sustainable long-term growth. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs GAS [BUY +25.0%] - Strong Volume Recovery to Boost 2026 Core NPAT KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. BMP [BUY +20.3%] - 2026F Earnings to Hit New Record High on Weak Input Costs We upgrade our rating for BMP to BUY from OUTPERFORM and raise our target price (TP) by 24% to VND192,500/share. The share price has risen 14% over the past two months. Our higher TP is due to (1) rolling our TP forward to end-2026 and (2) raising our 2026-30F NPAT-MI forecasts by ~20% each year. The higher earnings forecast is mainly driven by our higher GPM forecasts of ~3.5 percentage points each year during this period, respectively. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. Coupang: Facing Increasing Risk of a Potential Ban on Early Dawn Deliveries - Number One Risk Factor Topline Flash Note: Bank of Punjab (BOP): Corporate Briefing Key Takeaways The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential 1. KDH [BUY +42.2%] - Strong Land Bank Monetization to Boost Earnings Growth We reiterate our BUY rating for KDH and raise our target price (TP) by 3% to VND48,500/share. Our higher TP is mainly driven by a higher valuation for Binh Trung Dong, increased book value for undisclosed pipeline, and rolling our TP horizon forward to end-2026. We forecast 2025F NPAT-MI of VND1.04tn (USD39.5mn; +29% YoY; +1% vs prior), with Q4 2025F NPAT-MI of VND484bn (USD18mn; 2x QoQ and +22% YoY), driven by continued handovers of presold low-rise units at ‘Gladia by the Waters’ (11.8 ha; JV with Keppel; KDH 51%).

In this briefing: UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Capillary Technologies India IPO- Forensic Analysis Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Shadowfax Technologies Pre-IPO Tearsheet 1. UPI’s Next Act: How Credit Lines Could Reshape India’s Retail Lending Landscape RBI and NPCI are rolling out the Credit Line on UPI (CLOU) , allowing instant digital credit within UPI apps- effectively merging payments and lending. CLOU leverages India’s most trusted digital infrastructure to expand formal credit access , especially for new-to-credit consumers , and could be the foundation for a data-driven lending model. By combining UPI Credit Lines with a forthcoming Digital Payment Score (DPS) , India may transition from a payments-led to a credit-led digital economy - redefining financial inclusion and retail lending economics. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.

In this briefing: Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Primer: Tracxn Technologies (TRACXN IN) - Nov 2025 Primer: Hyundai Engineering (064540 KS) - Nov 2025 Primer: Zedcor (ZDC CN) - Nov 2025 1. Silergy (6415.TT): 4Q25 Flat or Slightly Upside; Early Gen4 Yields Remain Non-Comparable. 4Q25 seasonal outlook? Silergy expects flat to slightly up QoQ, similar to past years. Silergy does see consolidation, and given its stronger financials, product breadth, and R&D capabilities, the company remains a top supplier and will continue to gain share. Will 1H next year be better than 2H this year?Hard to say because of Chinese New Year seasonality.We expect YoY growth, but not strong yet. 2. The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a ' Zero 483 Observation' clearance from the USFDA , completely de-risking its largest-ever capex.